(HealthDay News) — Factors predicting greater prostate-specific antigen (PSA) increases with use of testosterone gel (T-gel) include age ≥60 years, baseline testosterone (T) ≤250ng/dL, and percentage of free PSA <20%, according to a study published in the November issue of the Journal of Sexual Medicine.

Abraham Morgentaler, MD, from Harvard Medical School in Boston, and colleagues evaluated 274 hypogonadal adult men (mean age, 53.5 years) with baseline T concentrations <300ng/dL, PSA ≤2.5ng/mL, and a negative digital rectal examination. The men were randomized to receive either once-daily T-gel for T therapy (234 participants) or placebo (40 participants).

The researchers found that baseline mean T values were 247ng/dL, while mean PSA levels were 0.9ng/mL and mean percentage of free PSA (%fPSA) was 24.6. Among men treated with T-gel, there were increases in T and PSA (P=0.0012). Compared to baseline, in the placebo group, T increased, while PSA decreased. The PSA increase was greater in men ≥60 years than in men <60 years (P=0.0006). Mean PSA only changed in men with baseline T ≤250ng/dL (P=0.0031). In men with baseline %fPSA <20%, PSA increased 0.3ng/mL, while it increased 0.1ng/mL in men with %fPSA ≥20%.

“Overall, T-gel treatment was associated with a minor increase in PSA, of questionable clinical significance,” the authors write. “Men with T >250ng/dL and age <60 years demonstrated minimal or no PSA change.”

Several authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)